Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study

Mariano Serrao, Alberto Ranavolo, Carmela Conte, Chiara Davassi, Silvia Mari, Alfonso Fasano, Giorgia Chini, Gianluca Coppola, Francesco Draicchio, Francesco Pierelli

Research output: Contribution to journalArticle

Abstract

The aim of this study was to investigate the effect of a rotigotine transdermal patch on stationary and non-stationary locomotion in de novo Parkinson disease (PD) patients in an open-label uncontrolled study. A 3-D gait analysis system was used to investigate four different locomotor tasks: steady-state linear walking, gait initiation, gait termination and 180°-turning. A series of gait variables were measured for each locomotor task. PD patients who received rotigotine treatment (4–8 mg) displayed: (1) increased step length, gait speed, cadence and arm oscillations, and reduced double support duration and step asymmetry during steady-state linear gait; (2) increased initial step length during gait initiation; (3) increased final step length and gait speed, and decreased stability index during gait termination; (4) decreased duration of turning and head–pelvis delays during 180°-turning. The main finding that emerges from the present study is that the dopamine agonist rotigotine can improve various aspects of gait in de novo PD patients.

Original languageEnglish
Pages (from-to)2539-2547
Number of pages9
JournalJournal of Neurology
Volume262
Issue number11
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Locomotion
Gait
Parkinson Disease
Therapeutics
Transdermal Patch
N 0437
Dopamine Agonists
Walking

Keywords

  • 3-D gait analysis
  • De novo Parkinson
  • Kinematics
  • Non-stationary locomotion
  • Rotigotine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study. / Serrao, Mariano; Ranavolo, Alberto; Conte, Carmela; Davassi, Chiara; Mari, Silvia; Fasano, Alfonso; Chini, Giorgia; Coppola, Gianluca; Draicchio, Francesco; Pierelli, Francesco.

In: Journal of Neurology, Vol. 262, No. 11, 01.11.2015, p. 2539-2547.

Research output: Contribution to journalArticle

Serrao, Mariano ; Ranavolo, Alberto ; Conte, Carmela ; Davassi, Chiara ; Mari, Silvia ; Fasano, Alfonso ; Chini, Giorgia ; Coppola, Gianluca ; Draicchio, Francesco ; Pierelli, Francesco. / Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study. In: Journal of Neurology. 2015 ; Vol. 262, No. 11. pp. 2539-2547.
@article{44184398304d43fa93bdb5376cfe7ce5,
title = "Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study",
abstract = "The aim of this study was to investigate the effect of a rotigotine transdermal patch on stationary and non-stationary locomotion in de novo Parkinson disease (PD) patients in an open-label uncontrolled study. A 3-D gait analysis system was used to investigate four different locomotor tasks: steady-state linear walking, gait initiation, gait termination and 180°-turning. A series of gait variables were measured for each locomotor task. PD patients who received rotigotine treatment (4–8 mg) displayed: (1) increased step length, gait speed, cadence and arm oscillations, and reduced double support duration and step asymmetry during steady-state linear gait; (2) increased initial step length during gait initiation; (3) increased final step length and gait speed, and decreased stability index during gait termination; (4) decreased duration of turning and head–pelvis delays during 180°-turning. The main finding that emerges from the present study is that the dopamine agonist rotigotine can improve various aspects of gait in de novo PD patients.",
keywords = "3-D gait analysis, De novo Parkinson, Kinematics, Non-stationary locomotion, Rotigotine",
author = "Mariano Serrao and Alberto Ranavolo and Carmela Conte and Chiara Davassi and Silvia Mari and Alfonso Fasano and Giorgia Chini and Gianluca Coppola and Francesco Draicchio and Francesco Pierelli",
year = "2015",
month = "11",
day = "1",
doi = "10.1007/s00415-015-7883-4",
language = "English",
volume = "262",
pages = "2539--2547",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "11",

}

TY - JOUR

T1 - Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study

AU - Serrao, Mariano

AU - Ranavolo, Alberto

AU - Conte, Carmela

AU - Davassi, Chiara

AU - Mari, Silvia

AU - Fasano, Alfonso

AU - Chini, Giorgia

AU - Coppola, Gianluca

AU - Draicchio, Francesco

AU - Pierelli, Francesco

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The aim of this study was to investigate the effect of a rotigotine transdermal patch on stationary and non-stationary locomotion in de novo Parkinson disease (PD) patients in an open-label uncontrolled study. A 3-D gait analysis system was used to investigate four different locomotor tasks: steady-state linear walking, gait initiation, gait termination and 180°-turning. A series of gait variables were measured for each locomotor task. PD patients who received rotigotine treatment (4–8 mg) displayed: (1) increased step length, gait speed, cadence and arm oscillations, and reduced double support duration and step asymmetry during steady-state linear gait; (2) increased initial step length during gait initiation; (3) increased final step length and gait speed, and decreased stability index during gait termination; (4) decreased duration of turning and head–pelvis delays during 180°-turning. The main finding that emerges from the present study is that the dopamine agonist rotigotine can improve various aspects of gait in de novo PD patients.

AB - The aim of this study was to investigate the effect of a rotigotine transdermal patch on stationary and non-stationary locomotion in de novo Parkinson disease (PD) patients in an open-label uncontrolled study. A 3-D gait analysis system was used to investigate four different locomotor tasks: steady-state linear walking, gait initiation, gait termination and 180°-turning. A series of gait variables were measured for each locomotor task. PD patients who received rotigotine treatment (4–8 mg) displayed: (1) increased step length, gait speed, cadence and arm oscillations, and reduced double support duration and step asymmetry during steady-state linear gait; (2) increased initial step length during gait initiation; (3) increased final step length and gait speed, and decreased stability index during gait termination; (4) decreased duration of turning and head–pelvis delays during 180°-turning. The main finding that emerges from the present study is that the dopamine agonist rotigotine can improve various aspects of gait in de novo PD patients.

KW - 3-D gait analysis

KW - De novo Parkinson

KW - Kinematics

KW - Non-stationary locomotion

KW - Rotigotine

UR - http://www.scopus.com/inward/record.url?scp=84956840771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956840771&partnerID=8YFLogxK

U2 - 10.1007/s00415-015-7883-4

DO - 10.1007/s00415-015-7883-4

M3 - Article

C2 - 26303834

AN - SCOPUS:84956840771

VL - 262

SP - 2539

EP - 2547

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 11

ER -